Orpharma has signed an
exclusive distribution agreement
with French company Lucane
Pharma for Pheburane.
The agreement covers
Australia and New Zealand for
the medication, which is used
for the treatment of Urea Cycle
Disorders involving deficiencies of
carbamylphosphate synthetase,
ornithine transcarbamylase and
argininosuccinate synthetase.
An Orpharma spokesperson said
there were about 15 identified
patients in Australia.
Orpharma said it would seek
registration with the TGA, the
outcome of which would likely
occur within 14 to 18 months, the
spokesperson said.
Prior to this, the product would
be available under the special
access scheme.The above article was sent to subscribers in Pharmacy Daily's issue from 16 Apr 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Apr 14
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.